Cutaneous side-effects of kinase inhibitors and blocking antibodies

Lancet Oncology

Volumn 6, Issue 7, 2005, Pages 491-500

  Robert, Caroline ^a   Soria, Jean Charles ^a   Spatz, Alain ^a   Le Cesne, Axel ^a   Malka, David ^a   Pautier, Patricia ^a   Wechsler, Janine ^b   Lhomme, Catherine ^a   Escudier, Bernard ^a   Boige, Valérie ^a   Armand, Jean Pierre ^a   Le Chevalier, Thierry ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETAMETHASONE; BLOCKING ANTIBODY; CETUXIMAB; CLINDAMYCIN; DIURETIC AGENT; DOXYCYCLINE; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROMYCIN; GEFITINIB; IMATINIB; KETOCONAZOLE; LAPATINIB; METRONIDAZOLE; PANITUMUMAB; PERTUZUMAB; PHOSPHOTRANSFERASE INHIBITOR; SORAFENIB; STEROID; SUNITINIB; UNCLASSIFIED DRUG; UREA;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DIURETIC THERAPY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENZYME INHIBITION; ERYTHEMA; EYELID EDEMA; FACE; FACE EDEMA; FLUID RETENTION; FOLLICULITIS; GASTROINTESTINAL STROMAL TUMOR; HAIR DISEASE; HAIR GROWTH; HISTOPATHOLOGY; HUMAN; KIDNEY CANCER; LICHENOID ERUPTION; LONG TERM CARE; LYMPHOCYTIC INFILTRATION; MELANOMA; NAIL DISEASE; NONHUMAN; PAPULE; PARONYCHIA; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PUSTULE; PUSTULOSIS; RETINA EDEMA; RISK FACTOR; SKIN DISEASE; SKIN NECROSIS; SKIN PIGMENTATION; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; THYROID CANCER; VASCULITIS; XEROSIS;

EID: 21344462378     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70243-6     Document Type: Review

References (76)

1. GD Demetri M von Mehren CD Blanke et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472-480
2. R Perez-Soler Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Huntingt) 17 suppl 12 2003 23-28
3. C Robert A Spatz S Faivre et al. Tyrosine kinase inhibition and grey hair Lancet 361 2003 1056
4. RS Herbst M Fukuoka J Baselga Gefitinib: A novel targeted approach to treating cancer Nat Rev Cancer 4 2004 956-965
5. J Mendelsohn J Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787-2799
6. DR Spigel JD Hainsworth JA Sosman Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial Proc Am Soc Clin Oncol 2005 abstr 4540.
7. P Pautier F Joly P Kerbrat et al. Preliminary results of a phase II study to evaluate gefitinib (ZD1839) combined with paclitaxel (P) and carboplatin (C) as second-line therapy in patients (pts) with ovarian carcinoma (OC) Proc Am Soc Clin Oncol 22 2004 abstr 5015.
8. D Cunningham Y Humblet S Siena et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337-345
9. KJ Busam P Capodieci R Motzer et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 Br J Dermatol 144 2001 1169-1176
10. W Jacot D Bessis E Jorda et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours Br J Dermatol 151 2004 238-241
11. R Van Doorn G Kirtschig E Scheffer et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor Br J Dermatol 147 2002 598-601
12. J Albanell F Rojo S Averbuch et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition J Clin Oncol 20 2002 110-124
13. KK Mak SY Chan Epidermal growth factor as a biologic switch in hair growth cycle J Biol Chem 278 2003 26120-26126
14. R Murillas F Larcher CJ Conti et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure EMBO J 14 1995 5216-5223
15. F Mascia V Mariani G Girolomoni S Pastore Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation Am J Pathol 163 2003 303-312
16. C Robert TS Kupper Inflammatory skin diseases, T cells, and immune surveillance N Engl J Med 341 1999 1817-1828
17. R Perez-Soler A Chachoua LA Hammond et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238-3247
18. EE Cohen F Rosen WM Stadler et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 21 2003 1980-1987
19. MK Mohamed S Ramalingam Y Lin et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer Ann Oncol 16 2005 780-785
20. SA Chrysogelos Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells Nucleic Acids Res 21 1993 5736-5741
21. H Buerger F Gebhardt H Schmidt et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of EGFR is related to cytogenetic alterations and epithelial growth factor receptor expression Cancer Res 60 2000 854-857
22. F Gebhardt KS Zanker B Brandt Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1 J Biol Chem 274 1999 13176-13180
23. ML Amador D Oppenheimer S Perea et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors Cancer Res 64 2004 9139-9143
24. NT Shah MG Kris W Pao et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib J Clin Oncol 23 2005 165-174
25. J Koistinaho J Yrjanheikki T Kauppinen M Koistinaho Tetracycline derivatives as anti-inflammatory agents and potential agents in stroke treatment Ernst Schering Res Found Workshop 2004 101-115
26. T Krakauer M Buckley Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines Antimicrob Agents Chemother 47 2003 3630-3633
27. GW Amsden Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 55 2005 10-21
28. S Dueland T Sauer F Lund-Johansen et al. Epidermal growth factor receptor inhibition induces trichomegaly Acta Oncol 42 2003 345-346
29. DW Threadgill AA Dlugosz LA Hansen et al. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype Science 269 1995 230-234
30. M Sibilia EF Wagner Strain-dependent epithelial defects in mice lacking the EGF receptor Science 269 1995 234-238
31. A McLaren The microscopic appearance of waved-2 mouse hairs Genet Res 17 1971 257-260
32. M Almagro J del Pozo J Garcia-Silva et al. Eyelash length in HIV infected patients AIDS 17 2003 1695-1696
33. RR Valiathan MD Resh Expression of human immunodeficiency virus type 1 gag modulates ligand-induced downregulation of EGF receptor J Virol 78 2004 12386-12394
34. L Bonaccorsi V Carloni M Muratori et al. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR) Int J Cancer 112 2004 78-86
35. D Huang X Liu SR Plymate et al. Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12 Oncogene 23 2004 6881-6889
36. IK Mellinghoff I Vivanco A Kwon et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability Cancer Cell 6 2004 517-527
37. KR Kalli SV Bradley S Fuchshuber CA Conover Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: Possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer Gynecol Oncol 94 2004 705-712
38. KW Boucher K Davidson B Mirakhur et al. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody J Am Acad Dermatol 47 2002 632-633
39. R Baran Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects Clin Exp Dermatol 11 1986 148-152
40. F Bouscarat C Bouchard D Bouhour Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir N Engl J Med 338 1998 1776-1777
41. JS Lee RA Newman SM Lippman et al. Phase I evaluation of all-trans-retinoic acid in adults with solid tumors J Clin Oncol 11 1993 959-966
42. HA Ward GG Russo J Shrum Cutaneous manifestations of antiretroviral therapy J Am Acad Dermatol 46 2002 284-293
43. JF Sah RL Eckert RA Chandraratna EA Rorke Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1/2 activation J Biol Chem 277 2002 9728-9735
44. JI Song MN Lango JD Hwang et al. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines Cancer Res 61 2001 5919-5925
45. SH Hong CW Wong ML Privalsky Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor Mol Endocrinol 12 1998 1161-1171
46. BJ Druker M Talpaz DJ Resta et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031-1037
47. F Guilhot Indications for imatinib mesylate therapy and clinical management Oncologist 9 2004 271-281
48. T Ahmad T Eisen Kinase inhibition with BAY 43-9006 in renal cell carcinoma Clin Cancer Res 10 suppl 2004 S6388-S6392
49. SM Wilhelm C Carter L Tang et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099-7109
50. DB Mendel AD Laird X Xin et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327-337
51. AM O'Farrell TJ Abrams HA Yuen et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 2003 3597-3605
52. RJ Motzer BI Rini MD Michaelson et al. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial Proc Am Soc Clin Oncol 14 2004 abstr 4500.
53. E Nagore A Insa O Sanmartin Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management Am J Clin Dermatol 1 2000 225-234
54. JB Young EJ Will GP Mulley Splinter haemorrhages: Facts and fiction J R Coll Physicians Lond 22 1988 240-243
55. MM Platts MS Greaves Splinter haemorrhages Br Med J 34 1958 143-144
56. F Mujic M Lloyd MJ Cuadrado et al. Prevalence and clinical significance of subungual splinter haemorrhages in patients with the antiphospholipid syndrome Clin Exp Rheumatol 13 1995 327-331
57. JG Quenneville D Gossard Subungueal-splinter hemorrhage an early sign of thromboangiitis obliterans Angiology 32 1981 424-432
58. BE Monk The prevalence of splinter haemorrhages Br J Dermatol 103 1980 183-185
59. D Heath DR Williams Nail haemorrhages Br Heart J 40 1978 1300-1305
60. BF Martin MM Platts A histological study of the nail region in normal human subjects and in those showing splinter haemorrhages of the nail J Anat 93 1959 323-330
61. C Robert, Faivre, S, Raymond, E, et al. VEGF-receptor inhibition and subungual splinter hemorrhages (in press).
62. KG Moss GC Toner JM Cherrington et al. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans J Pharmacol Exp Ther 307 2003 476-480
63. NV Botchkareva M Khlgatian BJ Longley et al. SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit FASEB J 15 2001 645-658
64. D Luo H Chen G Searles K Jimbow Coordinated mRNA expression of c-Kit with tyrosinase and TRP-1 in melanin pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by Kit/SCF-R Melanoma Res 5 1995 303-309
65. AA Sharov GZ Li TN Palkina et al. Fas and c-kit are involved in the control of hair follicle melanocyte apoptosis and migration in chemotherapy-induced hair loss J Invest Dermatol 120 2003 27-35
66. TJ Hemesath ER Price C Takemoto et al. MAP kinase links the transcription factor microphthalmia to c-Kit signalling in melanocytes Nature 391 1998 298-301
67. G Etienne P Cony-Makhoul FX Mahon Imatinib mesylate and gray hair N Engl J Med 347 2002 446
68. M Wu TJ Hemesath CM Takemoto et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi Genes Dev 14 2000 301-312
69. L Valeyrie S Bastuji-Garin J Revuz et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients J Am Acad Dermatol 48 2003 201-206
70. AS Tsao H Kantarjian J Cortes et al. Imatinib mesylate causes hypopigmentation in the skin Cancer 98 2003 2483-2487
71. ML Hensley JM Ford Imatinib treatment: Specific issues related to safety, fertility, and pregnancy Semin Hematol 40 suppl 3 2003 21-25
72. R Goldsby M Pulsipher R Adams et al. Unexpected pleural effusions in 3 pediatric patients treated with STI-571 J Pediatr Hematol Oncol 24 2002 694-695
73. M Ebnoether J Stentoft J Ford et al. Cerebral oedema as a possible complication of treatment with imatinib Lancet 359 2002 1751-1752
74. LM Khachigian Y Takuwa T Collins Mechanisms of angiotensin II-induced platelet-derived growth factor gene expression Mol Cell Biochem 212 2000 183-186
75. R Heuchel A Berg M Tallquist et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling Proc Natl Acad Sci USA 96 1999 11410-11415
76. FW Fraunfelder J Solomon BJ Druker et al. Ocular side-effects associated with imatinib mesylate (Gleevec) J Ocul Pharmacol Ther 19 2003 371-375